Lawrence R. Dick

Biochemistry, Genetics and Molecular Biology · Life Sciences

42h-index13.2kcitations94works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Ubiquitin and proteasome pathways(70), Peptidase Inhibition and Analysis(26), Protein Degradation and Inhibitors(14), Glycosylation and Glycoproteins Research(12), Cancer-related Molecular Pathways(9)

Publications94 total

A potent and selective reaction hijacking inhibitor of Plasmodium falciparum tyrosine tRNA synthetase exhibits single dose oral efficacy in vivo
PLoS Pathogens·2024· 2 citedOpen Access
A potent and selective reaction hijacking inhibitor of <i>Plasmodium falciparum</i> tyrosine tRNA synthetase exhibits single dose oral efficacy <i>in vivo</i>
2024Open Access
Supplementary Fig. S1 from Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
2023Open Access
Data from Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
2023Open Access
Supplementary Table S1 from Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
2023Open Access
Supplementary Table S1 from Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
2023Open Access
Supplementary Fig. S2 from Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
2023Open Access
Supplementary Fig. S1 from Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
2023Open Access
Supplementary Fig. S2 from Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
2023Open Access
Data from Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib
2023Open Access
Supplementary Figure 1 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
2023Open Access
Data from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
2023Open Access
Supplementary Data, Figure Legends 1-3 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
2023Open Access
Data from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
2023Open Access
Supplementary Figure 2 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
2023Open Access
Supplementary Figure 3 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
2023Open Access
Supplementary Figure 1 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
2023Open Access
Supplementary Figure 2 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
2023Open Access
Supplementary Figure 3 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
2023Open Access
Supplementary Data, Figure Legends 1-3 from Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Christopher Tsu(13), James E. Brownell(9), Frank J. Bruzzese(9), James M. Gavin(8), Michael D. Sintchak(8), Paul Hales(8), Ross L. Stein(7), Michael A. Milhollen(7), Alexandra E. Gould(7), Teresa A. Soucy(6), Steven Langston(6), Paul Fleming(6), Nancy J. Bump(6), Neil Bence(6), Stanley C. Xie(6), Leann Tilley(6), Mark Rolfe(5), Joseph B. Bolen(5), Louis Grenier(5), Mark Manfredi(5)